Summary: Axsome Therapeutics Inc presented data at NEI Congress 2024 on solriamfetol’s impact on excessive daytime sleepiness and cognitive function in patients with obstructive sleep apnea and narcolepsy. These findings, part of Axsome’s broader research portfolio, included insights from both real-world studies and clinical trials. Notable presentations focused on solriamfetol’s impact on wakefulness and cognitive outcomes in patients experiencing anxiety, depression, or impaired cognition due to sleep disorders.
Key Takeaways:
- Solriamfetol Reduces Daytime Sleepiness: Axsome presented data from the SURWEY study on solriamfetol’s impact in reducing excessive daytime sleepiness in patients with narcolepsy and OSA who have anxiety and depression.
- Improves Cognitive Function in OSA: Findings from the SHARP trial demonstrated that solriamfetol may enhance cognitive performance in patients with OSA and excessive daytime sleepiness.
- Research Portfolio: Axsome’s presentations also included research into major depressive disorder and Alzheimer’s disease agitation.
Axsome Therapeutics Inc presented findings on solriamfetol’s impact on excessive daytime sleepiness and cognitive function in patients with narcolepsy and obstructive sleep apnea as part of eight presentations given at the NEI Congress 2024.
Solriamfetol, sold under the brand name Sunosi, is a wakefulness-promoting medication used in the treatment of excessive sleepiness related to narcolepsy and sleep apnea.
Details for sleep medicine-related presentations were as follows:
OSA and Narcolepsy
Title: Solriamfetol for excessive daytime sleepiness in patients with narcolepsy and OSA reporting anxiety and depression in the real-world SURWEY study
Lead author: Ulf Kallweit, MD, assistant professor of neurology at the University Witten/Herdecke, Germany
Poster number: 98
Cognition
Title: Effects of solriamfetol on cognition in obstructive sleep apnea with excessive daytime sleepiness and impaired cognition in the SHARP clinical trial
Lead author: Yaroslav Winter, MD, Mainz Comprehensive Epilepsy and Sleep Medicine Center, department of neurology, Johannes Gutenberg-University, Mainz, Germany
Poster number: 103
Title: Effects of solriamfetol on cognition in patients with excessive daytime sleepiness associated with narcolepsy in the real-world SURWEY study
Lead author: Yaroslav Winter, MD, Mainz Comprehensive Epilepsy and Sleep Medicine Center, department of neurology, Johannes Gutenberg-University, Mainz, Germany
Poster number: 97
Other presentations were given spanning Axsome’s portfolio, including research in major depressive disorder and Alzheimer’s disease agitation.
Photo caption: Sunosi (solriamfetol)
File photo/Axsome Therapeutics
Further Reading for You:
Related posts:
Leave a Reply